Table 5.
Univariate/multivariate analyses of factors associated with prognosis in the p-DCS group
Univariate analysis | Multivariate analysis | |||||||
---|---|---|---|---|---|---|---|---|
Variable | No. of patients | HR | 95% CI | P value | HR | 95% CI | P value | |
Age (years) | ≥70 | 15 | 1.470 | (0.607–3.560) | 0.393 | |||
<70 | 24 | |||||||
Gender | Male | 32 | 0.409 | (0.156–1.075) | 0.070 | 0.281 | (0.093–0.846) | 0.024 |
Female | 7 | |||||||
ECOG performance status | ≥1 | 2 | 0.894 | (0.119–6.698) | 0.913 | |||
0 | 37 | |||||||
Borrmann macroscopic type | Non-type 4 | 38 | 0.452 | (0.059–3.439) | 0.443 | |||
Type 4 | 1 | |||||||
Differentiation | Diffuse | 18 | 0.758 | (0.310–1.854) | 0.543 | |||
Intestinal | 21 | |||||||
PAN metastasis | (+) | 16 | 1.869 | (0.539–4.854) | 0.201 | |||
(−) | 23 | |||||||
Hepatic metastasis | (+) | 9 | 2.508 | (0.993–6.333) | 0.052 | 1.718 | (0.530–5.570) | 0.367 |
(−) | 30 | |||||||
RECIST | SD, PD | 10 | 1.769 | (0.705–4.439) | 0.225 | |||
CR, PR | 29 | |||||||
Histological evaluation | 0, 1a, 1b | 17 | 2.84 | (1.152–7.000) | 0.023 | 1.938 | (0.612–6.129) | 0.260 |
2, 3 | 22 | |||||||
CD42b expression | ≥10% | 24 | 3.644 | (1.213–10.95) | 0.021 | 4.406 | (1.325–14.65) | 0.016 |
<10% | 15 | |||||||
Podoplanin expression | (+) | 28 | 1.411 | (0.512–3.889) | 0.505 | |||
(−) | 11 | |||||||
SNAIL expression | (+) | 30 | 1.736 | (0.664–4.539) | 0.261 | |||
(−) | 9 | |||||||
FOXP3 expression | (+) | 7 | 1.272 | (0.369–4.386) | 0.703 | |||
(−) | 32 |
CI confidence interval, CR complete response, ECOG Eastern Cooperative Oncology Group, FOXP3 forkhead box P3, HR hazard ratio, PD progressive disease, PR partial response, RECIST Response Evaluation Criteria in Solid Tumors, SD stable diseases